Insights & news

U.S. Department of Health and Human Services Announces International Pricing Index Model to Lower U.S. Medicine Cost

  • 29/10/2018
  • Articles

On 25 October 2018, the U.S. Department of Health and Human Services (“HHS”) announced the International Pricing Index (“IPI”) Model as a new tool to lower the cost of physician-administered medicines in the U.S.. According to HHS, the IPI Model is based on international prices of medicines and on a degree of competition in the value chain between medicine suppliers and healthcare providers introduced by private-sector vendors. It will now form the subject of public consultations.

The international pricing component stems from findings in an HHS study that the US is paying 1.8 times as much as a range of other wealthy countries for medicines. For 19 of 27 products studied, the U.S. paid more than any of the other countries “with similar economic conditions” under review. To remedy what President Trump calls “foreign freeloading” resulting from supposedly extortionist pricing practices vis-à-vis US medicine producers, the IPI Model will set a sample of medicines at a Target Price which, in turn, will be determined on the basis of discounts given by medicine firms to other countries. The Target Price will amount to 126% of the average price which other countries pay for a given medicine. The Model will be phased in over 5 years and will start in 50% of the U.S. before being scaled up.

The HHS study underpinning the IPI Model includes 14 EU countries, Canada and Japan. The EU countries mirror Germany’s external reference pricing basket (minus Denmark and The Netherlands). The products selected are, broadly, the top 20 medicines sold under the Medicare programme for the elderly, including single-source medicines, biological medicines and biosimilar products.

One of the stated goals of the IPI Model is to “[a]ddress the disparity in drug prices between the U.S. and other countries”. While it is clear this effort is expected to lead to lower medicine prices in the U.S. (overall savings for U.S. taxpayers and patients are projected to total $17.2 billion over a period of 5 years), higher medicine prices overseas (or, alternatively, a reduction in the availability of specific medicines in foreign countries) cannot be ruled out.

The IPI Model follows the May 2018 publication of the U.S. government policy paper “American Patients First” which had already decried the “foreign governments’ free-riding off American investment in innovation” (see, our article of 14 May 2018).

The following publications are attached by way of background:

  • HHS study “Comparison of U.S. and International Prices for Top Medicare Part B Drugs by Total Expenditures” – 25 October 2018;
  • HHS press release “HHS Advances Payment Model to Lower Drug Costs for Patients” – 25 October 2018;
  • HHS press release “What You Need to Know about President Trump Cutting Down on Foreign Freeloading” – 25 October 2018;
  • Advance Notice of Proposed Rulemaking “International Pricing Index Model for Medicare Part B Drugs” – undated; not yet published in Federal Register.

Key contacts

Related insights

Sign up for updates
    • 18/07/2019
    • Articles

    Transatlantic Cooperation on Medicines - Latest Developments

    A visit to Canada by the Dutch Minister for Medical Care, Bruno Bruins, has given rise to interesting news regarding international cooperation on medicine pricing. According to the attached press release of 17 July 2019, The Netherlands is spearheading an effort to have Canada sign up to the Beneluxa initiative on medicines ( Beneluxa is an international alliance for pharmaceutical policy composed of Austria, Belgium, Ireland, Luxembourg and The Netherlands. Medicine pricing is one of the pillars of Beneluxa along with other areas such as horizon scanning. A possible transatlantic contribution to Beneluxa by Canada would undoubtedly add considerable economic weight to the grouping and to the pricing negotations which it initiates. At the same time, it would create a further layer of technical complexity that may cause an already cumbersome organisation to become entirely unwieldy. Separately, Canada also wants to participate in the International Horizon Scanning Initiative (“IHSI”) in which countries from the Beneluxa group and others seek to identify innovative medicines before they reach the market. The initiative is supposed to inform decision-making on treatment choices and prepare members for tough budgetary discussions. An announcement on the countries that will participate in IHSI is scheduled for October 2019.

    Read more
    • 15/07/2019
    • Articles

    Belgium - Request for Premiums and Benefits by Hospitals from Suppliers of Medicines and Medical Devices in Public Procurement Proceedings

    The Federal Agency for Medicines and Health Products (“FAMHP”) has recently come out against hospitals requesting premiums and benefits from firms participating in tender proceedings for the supply of medicines and/or medical devices. According to FAMHP, that practice is not only prohibited by Article 81 of the Law of 17 June 2016 on Public Procurement, but may also run foul of Article 10 of the Law of 25 March 1964 regarding Medicines. At issue is the widespread practice indulged in by hospitals to ask prospective suppliers of medicines or medical devices to take care of unrelated goods and services such as the supply of educational materials and software for patient management or to pay for outreach activities organised by the hospitals. Article 81 of the Law of 17 June 2016 on Public Procurement provides in relevant part that the award criteria of a request for tenders should be connected to the subject of the public procurement procedure. For its part, Article 10 of the Law of 25 March 1964 regarding Medicines prohibits firms, subject to exceptions, from offering or providng benefits in cash or in kind to specific healthcare professionals and institutions in connection with the prescription, administration or supply of medicines or medical devices. Similarly, healthcare professionals and institutions are banned from soliciting or receiving such benefits. Based on a combined reading of these provisions, FAMHP maintains that it is not possible to offer or request free additional services with the supply of medicines or medical devices. According to FAMHP, additional services have to (i) come at a price; or (ii) and this is a puzzling addition, “have to present a cost which expressly forms part of the price of the goods”. Importantly, the services have to present a connection with the goods supplied. FAMHP indicates that this implies that outreach activities or additional software are “not admissible”. It adds that “free competition” should be guaranteed at all times and that a hospital should be able to justify the use of a specific award criterion. In other words, the hospital does not benefit from discretionary powers when crafting and then implementing a procurement procedure. Attached are a circular letter of FAMHP on the subject as well as an opinion delivered earlier this year by the committee for public procurement, an advisory body, which informed the point of view of FAMHP.

    Read more
    • 12/07/2019
    • Articles

    Slovakia Final Member State To Benefit From EU-US Mutual Recognition Agreement For Inspections of Manufacturing Sites For Human Medicines

    Slovakia has become the 28th and final EU Member State to be given the powers to carry out good manufacturing practice (“GMP”) inspections at a level equivalent to that prevailing in the US (see attached press release). On 11 July 2019, the US Food and Drug Administration (“FDA”) confirmed Slovakia’s status under the Mutual Recognition Agreement (“MRA”) governing GMP inspections of manufacturing sites for human medicines between the EU and the US. For their part, EU Member States have been able to rely on inspection results produced by the FDA since 1 November 2017. Pursuant to the MRA, the EU and the US now fully recognise inspections of manufacturing sites for human medicines carried out in each other’s territories. Separately, the batch testing waiver existing under the MRA will also start to apply. As a result, qualified persons in pharmaceutical firms based in Europe will no longer be required to carry out the quality controls when these have already been run in the US. The EU and US will continue implementation work for the MRA in hopes of extending its scope to a range of additional products, including veterinary medicines, human vaccines and plasma derived medicinal products.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *